Orthocell (ASX: OCC) has received US FDA 510(k) clearance for its nerve repair product, Remplir™, opening access to the US$1.6 billion US...

Argent BioPharma (ASX: RGT) has secured approval for its cannabinoid-based epilepsy treatment, CannEpil™, to be prescribed in Germany....

Race Oncology (ASX: RAC) has announced the activation of the first Australian clinical site for its Phase 1 trial of RC220, an innovative...

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) has secured U.S. Medicaid coverage for its FDA-approved mesenchymal stromal cell (MSC) therapy,...

Sydney-based Echo IQ (ASX: EIQ) has secured integration agreements with ScImage and MedAxiom, bringing its AI-driven EchoSolv AS...

Avecho Biotechnology (ASX: AVE) has secured a US$3 million upfront payment from Sandoz AG for exclusive rights to market its Phase III...

Mesoblast (ASX:MSB), announced that its flagship therapy, Ryoncil® (remestemcel-L), is now available for purchase in the United States....

Neuren Pharmaceuticals (ASX: NEU) is expanding its pipeline with a new initiative: developing NNZ-2591 to treat (HIE), a severe brain...

Opthea Ltd. (ASX/NASDAQ: OPT) announced that its COAST Phase 3 trial for wet age-related macular degeneration (wet AMD) failed to meet...

LTR Pharma (ASX: LTP) has hit a major regulatory milestone with the U.S. FDA while ramping up its commercial push in the U.S. and...

Immutep (ASX: IMM; NASDAQ: IMMP) has taken a major step forward in its pursuit of a groundbreaking lung cancer treatment, dosing the...

Beamtree Holdings (ASX: BMT) has won a five-year contract renewal worth AU$3.95 million (€2.3 million) to provide its market-leading...